Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · IEX Real-Time Price · USD
2.388
-0.032 (-1.32%)
Jul 22, 2024, 10:10 AM EDT - Market open
Galectin Therapeutics Employees
Galectin Therapeutics had 14 employees as of December 31, 2023. The number of employees increased by 2 or 16.67% compared to the previous year.
Employees
14
Change (1Y)
2
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$3,198,214
Market Cap
148.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
High Tide | 1,550 |
Lifecore Biomedical | 459 |
Quantum-Si incorporated | 159 |
Rani Therapeutics Holdings | 140 |
OptiNose | 132 |
Alpha Tau Medical | 121 |
Kodiak Sciences | 111 |
Vaxart | 109 |
GALT News
- 6 weeks ago - Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress - GlobeNewsWire
- 2 months ago - Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update - GlobeNewsWire
- 4 months ago - Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development - GlobeNewsWire
- 8 months ago - PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023 - Business Wire
- 9 months ago - UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update - GlobeNewsWire
- 9 months ago - Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update - GlobeNewsWire
- 9 months ago - Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD - GlobeNewsWire